Pfizer Files 8K - Changes Executive Management
February 23 2017 - 05:35PM
Dow Jones News
Pfizer Inc. (PFE) filed a Form 8K - Changes in Company Executive
Management - with the U.S Securities and Exchange Commission on
February 23, 2017.
On February 23, 2017, the Board of Directors of Pfizer Inc. (the
"Company") elected Ronald E. Blaylock to serve as a member of the
Company's Board of Directors, effective immediately. In addition,
he was elected to the Corporate Governance Committee and the
Science and Technology Committee of the Board.
Mr. Blaylock has been provided an indemnification agreement and
will receive compensation in accordance with the Company's standard
arrangements for non-employee directors. The press release, dated
February 23, 2017, announcing the election of Mr. Blaylock is
attached hereto as Exhibit 99.1 and is incorporated herein by
reference.
The full text of this SEC filing can be retrieved at:
http://www.sec.gov/Archives/edgar/data/78003/000007800317000015/nx8k223.htm
Any exhibits and associated documents for this SEC filing can be
retrieved at:
http://www.sec.gov/Archives/edgar/data/78003/000007800317000015/0000078003-17-000015-index.htm
Public companies must file a Form 8-K, or current report, with
the SEC generally within four days of any event that could
materially affect a company's financial position or the value of
its shares.
(END) Dow Jones Newswires
February 23, 2017 17:20 ET (22:20 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From Mar 2023 to Mar 2024